On Wednesday, driven by both the announcement of a new plant expansion and political developments, shares of pharmaceutical giant AbbVie (ABBV) rose nearly 6%, significantly outperforming the S&P 500 index, which gained a mere 0.3%.
On Tuesday afternoon, AbbVie announced the launch of an expansion project at its biotech research center in Worcester, Massachusetts. This $70 million investment aims to enhance the research, development, and production capacity for drugs in the pipeline, particularly in the biologics field. The project will expand existing production space and add a new three-story building to house warehouse, office, and laboratory facilities. The company stated that this move aligns with the Trump administration’s goal of encouraging more corporate assets within the United States and is a key part of its over $10 billion plan supporting biologics development. Chief Operating Officer Azita Saleki-Gerhardt noted that the project will solidify the company’s track record of excellence in developing, manufacturing, and launching the next generation of complex biologic medicines.
AbbVie also benefited from recent moves by its peer Pfizer. Pfizer CEO Albert Bourla has agreed to lower prices on some medicines and, due to commitments to increase investment in the U.S., received planned tariff relief for the pharmaceutical industry from the Trump administration. This development suggests that two major threats previously looming over the pharmaceutical industry – pricing pressure and tariff risks – might be less severe than initially feared, creating a more favorable external environment for companies like AbbVie.
Several predictions regarding AbbVie’s future are relatively clear. First, in five years, the company’s reliance on its long-standing blockbuster drug Humira will be significantly reduced. Since its biosimilars entered the U.S. market in 2023, Humira’s sales have been declining. Meanwhile, its successor products, Skyrizi and Rinvoq, are expected to become larger growth drivers, with their combined sales potentially exceeding $25 billion this year, possibly even surpassing Humira’s peak performance. Furthermore, other products in the pipeline, including the multiple myeloma drug Elahere, and the migraine treatments Qulipta and Ubrelvy, are also expected to maintain strong momentum. Regarding shareholder returns, AbbVie is expected to maintain its “Dividend King” status, potentially achieving a record of 58 consecutive years of dividend increases by 2030.
However, predicting AbbVie’s stock price or market capitalization five years from now is no easy task. In the short term, the Trump administration’s threat of imposing high tariffs on drugs imported into the U.S. could pressure company profits. Additionally, the overall economic outlook remains difficult to predict. Should an economic recession occur within the next five years, while AbbVie would likely be more resilient than most companies, its stock price would still struggle to remain immune in a broadly declining market. The R&D pipeline itself carries uncertainties; clinical trial results could disappoint, and the specifics of future mergers and acquisitions will also impact its stock performance.
Despite the aforementioned uncertainties, we can still make an educated speculation about AbbVie’s prospects. The company’s stock price is expected to achieve high single-digit average annual growth, with its market capitalization potentially increasing from the current approximately $390 billion to around $600 billion. With its attractive dividend, sustained growth potential, and relative resilience during market downturns, AbbVie is positioned to provide substantial returns for investors and could be a worthwhile stock to hold in many portfolios.
